Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.

The major drug-metabolizing human hepatic cytochrome P-450s (CYPs; CYP1A2, 2C9, 2C19, 2D6, and 3A4) coexpressed functionally in Escherichia coli with human NADPH-P-450 reductase have been validated as surrogates to their counterparts in human liver microsomes (HLM) using automated technology. The dealkylation of ethoxyresorufin, dextromethorphan, and erythromycin were all shown to be specific reactions for CYP1A2, CYP2D6, and CYP3A4 that allowed direct comparison with kinetic data for HLM. For CYP2C9 and CYP2C19, the kinetics for the discrete oxidations of naproxen and diazepam were compared to data obtained using established, commercial CYP preparations. Turnover numbers of CYPs expressed in E. coli toward these substrates were generally equal to or even greater than those of the major commercial suppliers [CYP1A2 (ethoxyresorufin), E. coli 0.6 +/- 0.2 min(-1) versus B lymphoblasts 0.4 +/- 0.1 min(-1); CYP2C9 (naproxen), 6.7 +/- 0.9 versus 4.9 min(-1); CYP2C19 (diazepam), 3.7 +/- 0.3 versus 0.2 +/- 0.1 min(-1); CYP2D6 (dextromethorphan), 4.7 +/- 0.1 versus 4.4 +/- 0.1 min(-1); CYP3A4 (erythromycin), 3 +/- 1.2 versus 1.6 min(-1)]. The apparent K(m) values for the specific reactions were also similar (K(m) ranges for expressed CYPs and HLM were: ethoxyresorufin 0.5-1.0 microM, dextromethorphan 1.3-5.9 microM, and erythromycin 18-57 microM), indicating little if any effect of N-terminal modification on the E. coli-expressed CYPs. The data generated for all the probe substrates by HLM and recombinant CYPs also agreed well with literature values. In summary, E. coli-expressed CYPs appear faithful surrogates for the native (HLM) enzyme, and these data suggest that such recombinant enzymes may be suitable for predictive human metabolism studies.

[1]  H. Yamazaki,et al.  Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. , 1995, Biochemistry.

[2]  C. Sengstag,et al.  Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[3]  H. Iwata,et al.  High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. , 1998, Biochemical pharmacology.

[4]  C. Wolf,et al.  A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. , 1997, Archives of biochemistry and biophysics.

[5]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[6]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[7]  A. D. Rodrigues,et al.  Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. , 1994, Analytical biochemistry.

[8]  D. Greenblatt,et al.  Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. , 1998, Journal of pharmaceutical sciences.

[9]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  B. Burchell,et al.  Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. , 1993, Biochemical pharmacology.

[11]  S. Clarke,et al.  Characterization of the inhibition of P4501A2 by furafylline. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  G. Tucker,et al.  Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. , 1995, Biochemical pharmacology.

[13]  R J Riley,et al.  Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  Eric F. Johnson,et al.  DIAZEPAM METABOLISM BY CDNA-Expressed Human 2 C P 450 S Identification of P 4502 C 18 and P 4502 C 19 as Low KM Diazepam N-Demethylases , 1997 .

[15]  A. Parkinson.  An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.

[16]  A. Y. Lu,et al.  Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[17]  H. Yamazaki,et al.  High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influence of membrane charge. , 1996, Biochemical and biophysical research communications.

[18]  S. Wolfe,et al.  Cisapride and torsades de pointes , 1995, The Lancet.

[19]  S. Wrighton,et al.  Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[20]  M. Rawlins,et al.  Ethoxyresorufin O-deethylation by human liver microsomes. , 1986, British journal of clinical pharmacology.

[21]  C. Logan,et al.  Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[22]  H. Yamazaki,et al.  Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. , 1997, Pharmacogenetics.

[23]  C. W. Fisher,et al.  Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Goldstein,et al.  Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. , 1997, Pharmacogenetics.

[25]  J. Houston,et al.  Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. , 1996, British journal of clinical pharmacology.

[26]  G. Schoenhard,et al.  Involvement of cytochrome P-450IIIA in metabolism of potassium canrenoate to an epoxide: mechanism of inhibition of the epoxide formation by spironolactone and its sulfur-containing metabolite. , 1993, The Journal of pharmacology and experimental therapeutics.

[27]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[28]  T. Richardson,et al.  A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. , 1995, Archives of biochemistry and biophysics.

[29]  K. Korzekwa,et al.  Cytochromes P450 Expression Systems , 1995 .

[30]  K. Korzekwa,et al.  Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. , 1990, Endocrinology.

[31]  T. Richardson,et al.  Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[32]  M. Yamanaka,et al.  Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. , 1986, Clinical chemistry.

[33]  B. W. Penman,et al.  Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. , 1997, Advances in pharmacology.

[34]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[35]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[36]  D. Greenblatt,et al.  Metabolism of Dextromethorphan in vitro: Involvement of Cytochromes P450 2D6 AND 3A3/4, with a Possible Role of 2E1 , 1997, Biopharmaceutics & drug disposition.

[37]  R. Tukey,et al.  Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. , 1992, Pharmacogenetics.

[38]  J. Blake,et al.  Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. , 1998, Pharmacogenetics.

[39]  R. Kato,et al.  Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.

[40]  C. W. Fisher,et al.  High‐level expression of functional human cytochrome P450 1A2 in Escherichia coli , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  C. Funck-Brentano,et al.  Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. , 1998, Pharmacogenetics.

[42]  S. Wrighton,et al.  Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation , 1997, European Journal of Clinical Pharmacology.

[43]  M. Waterman,et al.  Genetically engineered bacterial cells and applications. , 1995, Toxicology letters.

[44]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[45]  K. Korzekwa,et al.  Cytochromes P450 expression systems. , 1995, Annual review of pharmacology and toxicology.

[46]  T. Aoyama,et al.  Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  M. Waterman.  Heterologous expression of cytochrome P-450 in Escherichia coli. , 1993, Biochemical Society transactions.

[48]  A. Somogyi,et al.  The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. , 1994, British journal of clinical pharmacology.

[49]  F. Guengerich,et al.  Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. , 1993, Archives of biochemistry and biophysics.

[50]  R. Tukey,et al.  Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. , 1996, Biochemical pharmacology.

[51]  C. Funck-Brentano,et al.  CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. , 1993, Pharmacogenetics.

[52]  M. J. Coon,et al.  Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. , 1991, The Journal of biological chemistry.

[53]  A. D. Rodrigues,et al.  [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[54]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[55]  J. Miners,et al.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. , 1994, British journal of clinical pharmacology.

[56]  B. Tang,et al.  Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. , 1997, Biochemical pharmacology.

[57]  C. Wolf,et al.  Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli , 1996, FEBS letters.

[58]  R. Riley,et al.  In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin. , 1997, Journal of pharmacological and toxicological methods.

[59]  H K Kroemer,et al.  "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.